Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 2 September 2019. Larry Bieglesen.

Executive Summary

The US FDA has issued a safety communication to hospitals and providers to transition from using fixed endcap duodenoscopes to ones where the cap can be switched out. The directive from the agency is good news for Boston Scientific, which makes a disposable duodenoscope called Exalt-D that is close to being approved. See what Wells Fargo analyst Larry Bieglesen said about it here.

“Exalt-D is a single-use duodenoscope designed to eliminate the possibility of getting infection with a contaminated reusable scope. Given [the] FDA communication, we would expect approval of Exalt-D shortly.” – Larry Bieglesen, analyst, Wells Fargo

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel